Crossmark Global Holdings Inc. lessened its stake in Bioverativ Inc (NASDAQ:BIVV) by 20.1% in the 4th quarter, HoldingsChannel reports. The fund owned 13,939 shares of the biotechnology company’s stock after selling 3,498 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Bioverativ were worth $752,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Bioverativ during the 4th quarter worth approximately $105,000. American Assets Investment Management LLC acquired a new stake in shares of Bioverativ during the 4th quarter worth approximately $108,000. Advisors Asset Management Inc. acquired a new stake in shares of Bioverativ during the 3rd quarter worth approximately $137,000. TCI Wealth Advisors Inc. acquired a new stake in shares of Bioverativ during the 3rd quarter worth approximately $186,000. Finally, Ladenburg Thalmann Financial Services Inc. acquired a new stake in shares of Bioverativ during the 3rd quarter worth approximately $190,000. Institutional investors own 94.10% of the company’s stock.
BIVV has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a research report on Monday, January 8th. Piper Jaffray Companies reiterated an “overweight” rating and set a $71.00 price target on shares of Bioverativ in a research report on Monday, October 23rd. Royal Bank of Canada lifted their price target on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, January 18th. Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. Finally, Jefferies Group lifted their price target on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research report on Thursday, January 18th. Thirteen research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Bioverativ has a consensus rating of “Hold” and a consensus price target of $63.15.
TRADEMARK VIOLATION NOTICE: “Crossmark Global Holdings Inc. Lowers Holdings in Bioverativ Inc (BIVV)” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3205495/crossmark-global-holdings-inc-lowers-holdings-in-bioverativ-inc-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.